Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · December 28, 2022

Association of Immunogenicity With the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Biosimilar, SB11, and Reference Product

JAMA Ophthalmology


Additional Info

JAMA Ophthalmology
Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial
JAMA Ophthalmol 2022 Dec 15;[EPub Ahead of Print], NM Bressler, T Kim, I Oh, P Russo, MY Kim, SJ Woo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading